SynthesisHead and neck pathology2025
Oral and Maxillofacial Low-Grade Myofibroblastic Sarcoma: A Systematic Review.
Synthesis in Head and neck pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis systematic review (SR) aimed to summarize the clinical, histopathological, and immunohistochemical features of low-grade myofibroblastic sarcoma (LGMS) in the oral and maxillofacial region (OMR), as well as treatment protocols, recurrence, follow-up, and metastasis rates. It follows PRISMA 2022 guidelines and is registered in PROSPERO (CRD42023409758).
methodsAn electronic search included PubMed, EMBASE, Scopus, Web of Science, LILACS, Google Scholar, and ProQuest databases, and bias risk was assessed using the Joanna Briggs Institute tool. Statistical analyses, including Fisher's and Chi-Squared tests, were conducted to explore associations between clinical variables, and survival analysis was performed using the Kaplan-Meier method.
resultsForty-three studies covering 78 cases were included. LGMS showed a slight female predominance (51.28%) and an average patient age of 35.35 years. The most affected sites were the mandible (29.4%), maxilla (19.23%), and tongue (15.38%). Clinical presentations included masses (30.76%), tumors (26.92%), and swelling (12.82%), with symptom duration ranging from 1 week to 30 months. Surgery alone was the primary treatment (60.25%), with recurrence in 20.51% and metastasis in 5.12% of cases. One-year and 5-year overall survival rates were 92.6% and 71.8%, respectively. Surgery as the sole treatment was significantly associated with a lower metastasis rate (p = 0.005).
conclusionOur findings highlighted the importance of considering LGMS in differential diagnoses of myofibroblastic lesions and underscored the need for a comprehensive immunohistochemical analysis. Complete surgical excision remains the preferred treatment, though long-term follow-up is needed to better understand recurrence and metastasis risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.